子宫平滑肌肉瘤恶性潜能预测：CT与临床病理特征相关性研究
Prediction of Malignant Potential of Leiomyosarcoma: Correlation between Preoperative CT and Pathological Features
DOI: 10.12677/ACM.2021.113177, PDF,    科研立项经费支持
作者: 康 巍, 黄向阳*：广西医科大学附属肿瘤医院影像中心，广西 南宁；钟武宁*：广西医科大学附属肿瘤医院化疗五科，广西 南宁
关键词: 子宫平滑肌肉瘤；CT；组织病理学；Uteruses Leiomyosarcomas； Computed Tomography； Histopathology
摘要: 目的：分析子宫平滑肌肉瘤(uLMS) CT增强强化程度与Ki-67增值指数是否具有相关性。方法：回顾性分析14例uLMS的临床表现、CT特点、肿瘤标志物及病理特点，所有病例均经过病理证实。本文分析uLMS CT增强强化程度与Ki-67增值指数的相关性。结果：uLMS实性成分CT呈中度至明显强化，且与Ki67增殖指数具有明显的相关性(p < 0.05)。另外，大部分病人CA125值明显升高，且Desmin及SMA表达阳性。结论：对于uLMS CT强化程度及Ki67增值情况可能可以预测其恶性转化过程，CA125升高也能预测uLMS的恶性程度。
Abstract: Objective: To analyze the correlation between the degree of enhancement of leiomyosarcoma CT and Ki-67 value-added index. Methods: The clinical manifestations, CT features, tumor markers and pathological features of 14 cases of uLMS were analyzed retrospectively. All cases were confirmed by pathology. The correlation between the enhancement degree of uLMS CT and the value-added index of Ki-67 was analyzed. Results: The solid components of uLMS showed moderate to significant enhancement on CT, and there was a significant correlation between them and Ki-67 proliferation index (p < 0.05). In addition, CA125 was significantly elevated in most patients, and Desmin and SMA were positive. Conclusion: The enhancement of CT and the increase of Ki-67 may predict the malignant transformation of uLMS, and the increase of CA125 may also predict the malignant degree of uLMS.
文章引用：康巍, 黄向阳, 钟武宁. 子宫平滑肌肉瘤恶性潜能预测：CT与临床病理特征相关性研究[J]. 临床医学进展, 2021, 11(3): 1228-1234. https://doi.org/10.12677/ACM.2021.113177

参考文献

[1] Astolfi, A., Nannini, M., Indio, V., et al. (2020) Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. Cancers, 12, 2126. [Google Scholar] [CrossRef] [PubMed]
[2] Santos, P. and Cunha, T.M. (2015) Uterine Sarcomas: Clinical Presentation and MRI Features. Diagnostic and Interventional Radiology, 21, 4-9. [Google Scholar] [CrossRef] [PubMed]
[3] Allen, M.M., Douds, J.J., Liang, S.X., Desouki, M.M., Parkash, V. and Fadare, O. (2015) An Immunohistochemical Analysis of Stathmin 1 Expression in Uterine Smooth Muscle Tumors: Differential Expression in Leiomyosarcomas and Leiomyomas. International Journal of Clinical and Experimental Pathology, 8, 2795-2801.
[4] Pautier, P., Floquet, A., Chevreau, C., et al. (2015) Trabectedin in Combination with Doxorubicin for First-Line Treatment of Advanced Uterine or Soft-Tissue Leiomyosarcoma (LMS-02): A Non-Randomised, Multicentre, Phase 2 Trial. The Lancet Oncology, 16, 457-464. [Google Scholar] [CrossRef] 
[5] Sato, K., Yuasa, N., Fujita, M. and Fukushima, Y. (2014) Clinical Application of Diffusion-Weighted Imaging for Preoperative Differentiation between Uterine Leiomyoma and Leiomyosarcoma. American Journal of Obstetrics and Gynecology, 210, 368.e1-368.e8. [Google Scholar] [CrossRef] [PubMed]
[6] Leiser, A.L., Anderson, S.E., Nonaka, D., et al. (2006) Apoptotic and Cell Cycle Regulatory Markers in Uterine Leiomyosarcoma. Gynecologic Oncology, 101, 86-91. [Google Scholar] [CrossRef] [PubMed]
[7] Senol, T., Kahramanoglu, I., Muezzinoglu, B. and Yucesoy, I. (2016) Giant Leiomyosarcoma: A Case Report. International Journal of Surgery Case Reports, 19, 109-111. [Google Scholar] [CrossRef] [PubMed]
[8] 杨晓珍, 龙江, 赵鹏, 高文峰, 张永宏. 肝癌分化程度与肝脏CT强化特点及CD34、p53、GPC3、CK19、Ki-67表达的关系[J]. 癌症进展, 2018(15): 1892-1895.
[9] Knudsen, N.I., Wernecke, K.D., Siedentopf, F. and David, M. (2017) Fears and Concerns of Patients with Uterine Fibroids—A Survey of 807 Women. Geburtshilfe und Frauenheilkunde, 77, 976-983. [Google Scholar] [CrossRef] [PubMed]
[10] 王景宇, 冬冬, 戴春来, 王淑清, 周丹丹. 胃癌CT征象与组织分化及p53、Ki67表达的相关性[J]. 中国医学科学院学报, 2011(5): 555-559.
[11] 梁金晓, 林仲秋. 《FIGO 2018癌症报告》——子宫肉瘤诊治指南解读[J]. 中国实用妇科与产科杂志, 2018, 34(12): 1366-1371.
[12] Peters, A., Sadecky, A.M., Winger, D.G., et al. (2017) Characterization and Preoperative Risk Analysis of Leiomyosarcomas at a High-Volume Tertiary Care Center. International Journal of Gynecological Cancer, 27, 1183-1190. [Google Scholar] [CrossRef] 
[13] Ricci, S., Stone, R.L. and Fader, A.N. (2017) Uterine Leiomyosarcoma: Epidemiology, Contemporary Treatment Strategies and the Impact of Uterine Morcellation. Gynecologic Oncology, 145, 208-216. [Google Scholar] [CrossRef] [PubMed]
[14] 左艳, 闫彩平, 邓鹏飞, 管元香. 32例子宫肉瘤的临床特点与诊疗分析[J]. 中国实用医药, 2015, 10(18): 95-96.
[15] 朱熠, 石宇, 刘红, 王登凤, 向阳, 张国楠. 《实施腹腔镜下子宫(肌瘤)分碎术的中国专家共识》解读[J]. 肿瘤预防与治疗, 2020, 33(8): 633-637.
[16] Dai, H., Liu, J., Liang, L., et al. (2014) Increased Lung Cancer Risk in Patients with Interstitial Lung Disease and Elevated CEA and CA125 Serum Tumour Markers. Respirology, 19, 707-713. [Google Scholar] [CrossRef] [PubMed]
[17] Ahmadi, H., Djaladat, H., Cai, J., Miranda, G. and Daneshmand, S. (2014) Precystectomy Serum Levels of Carbohydrate Antigen 19-9, Carbohydrate Antigen 125, and Carcinoembryonic Antigen: Prognostic Value in Invasive Urothelial Carcinoma of the Bladder. Urologic Oncology, 32, 648-656. [Google Scholar] [CrossRef] [PubMed]
[18] 谢洁林, 田晓梅, 韩志刚, 张国福. 子宫肉瘤的MRI表现与临床病理分析[J]. 肿瘤影像学, 2014, 23(2): 95-98.
[19] Juang, C.M., Yen, M.S., Horng, H.C., Twu, N.F., Yu, H.C. and Hsu, W.L. (2006) Potential Role of Preoperative Serum CA125 for the Differential Diagnosis between Uterine Leiomyoma and Uterine Leiomyosarcoma. European Journal of Gynaecological Oncology, 27, 370-374.

为你推荐